Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia

Aug 17, 2023 | Press Releases

– 402 patients completed enrollment across multiple sites in the US, Europe, and Asia – – Topline data for Phase 3 RECOVER study expected in October 2023 – – Completion of 1-year open-label extension clinical study expected in Q3 2024...

Reviva Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 14, 2023 | Press Releases

– Topline data for global pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected in October 2023 – – Completion of 1-year open-label extension clinical trial for brilaroxazine in schizophrenia expected in Q3 2024 – CUPERTINO,...

Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in August

Jul 31, 2023 | Press Releases

CUPERTINO, Calif., July 31, 2023 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Pharmaceuticals to be Added to Russell Microcap® Index

Jun 26, 2023 | Press Releases

CUPERTINO, Calif., June 26, 2023 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Pharmaceuticals Announces 80% Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia

Jun 22, 2023 | Press Releases

– Enrollment ongoing at multiple sites in the US, Europe, and Asia – – Multifaceted activity of serotonin-dopamine stabilizer brilaroxazine supports potential for improvement in schizophrenia symptoms as well as accompanying neuroinflammation –...